ArticlePoultry science2026
E. coli-expressed chicken IL-17A enhances respiratory innate immunity by inducing proinflammatory cytokines and interferons.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-17A (IL-17A) is a key pro-inflammatory cytokine that plays a crucial and complex role in immune regulation, infection, and inflammation under both physiological and pathological conditions, demonstrating significant potential in these fields. However, research on its interaction with the avian respiratory system and its potential application as a mucosal immune adjuvant is limited. To investigate its functional relevance, a comparison was first performed of the genetic and structural features of chicken IL-17A (chIL-17A) with those of its mammalian homologs. Recombinant chIL-17A was subsequently produced via a prokaryotic expression system and evaluated through in vitro assays using chicken embryo fibroblasts (CEFs) and peripheral blood mononuclear cells (PBMCs), as well as in vivo experiments in specific-pathogen-free (SPF) chickens. In the in vivo study, 3-week-old SPF White Leghorn chickens (mixed sex) were nebulized with a single or double dose (20 μg/kg per dose, n = 12 per group) of chIL-17A. The results demonstrated that chIL-17A treatment markedly upregulated the transcription of proinflammatory cytokines (e.g., IL-1β, IL-6, and TNF-α), type I interferons, and multiple interferon-stimulated genes in a dose-and time-dependent manner. Notably, a second administration further enhanced its stimulatory effect on these immune mediators. In vivo, nebulized chIL-17A significantly induced pulmonary proinflammatory responses, particularly on day 5 post-treatment, with IL-1β and IL-6 mRNA levels increasing by 67.35-fold (P < 0.001) and 130.19-fold (P < 0.001), respectively, in lung tissues. Modulation of IFN responses was most pronounced in the lower trachea and lung tissues, with minimal effects in the upper tracheal region. These findings unequivocally demonstrate the potent immunomodulatory capacity of chIL-17A and underscore its potential as a mucosal immune enhancer in poultry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.